Predict S.p.a. Class B · MIL:PRE
Predict S.p.a. Class B — KT&Partners Annual Investors Summit Day 2025
31 slides from Predict S.p.a. Class B's conference presentation, Jun 12, 2025
Slide 1: Predict S.p.A. Investor Presentation
PREDICT S.P.A. Investor Presentation 12th June 2025 – KT&Partners | Annual Investors Summit Day
Slide 2: At a Glance
AT A GLANCE Hi-Tech solutions for advanced diagnostics 17years 23 Predict S.p.A., based in Bari, is an innovative SME active in the of partnership Highly healthcare sector, specializing in non-invasive in vivo diagnostics. with GE qualified €0.92mn employees 3 It markets medical imaging systems for
Slide 3: Milestones
MILESTONES 2008 PREDICT WAS DELIVERY OF FIRST FOUNDED SAMPLER 2025 AWARDED D3- 4HEALTH TENDER 2012 WITH THE ENDOSCOPE 2008 2016 2017 2018 2020 2021 2023 2024 PROJECT NEW DISTRIBUTION AFTER-SALES AGREEMENTS WITH SUBSCRIPTION OF DEVELOPMENT OF INSTALLATION PREDICTSTORE.IT STATUS AS SERVICES FOR GE CAR
Slide 4: Industry Business System and Business Model
INDUSTRY BUSINESS SYSTEM AND BUSINESS MODEL Predict offers a model based on the supply of innovative and high-tech solutions for the healthcare sector, ensuring a favorable ecosystem for widespread technological innovation processes. UNIVERSITIES PATIENTS SUPPLIERS IRCCS CUSTOMERS AND CITIZENS HOSPI
Slide 5: Strategic Business Units
STRATEGIC BUSINESS UNITS The activities of Predict are divided into 4 Strategic Business Units: Traditional Innovative SBU Imaging People Support Mistral Digital Healthcare • Sale of medical imaging • Technical assistance • Development, design, and • Development, design and equipment*, marketed in t
Slide 6: Products and Application Portfolio
PRODUCTS AND APPLICATION PORTFOLIO Predict is unique on the national scene, ensuring technological oversight of health data collected through medical devices and the developed equipment. Traditional Innovative People Support SBU Imaging Mistral Digital Healthcare Mistral Sampler Optip Surgery Optip
Slide 7: Synergies Between the Different SBUs
SYNERGIES BETWEEN THE DIFFERENT SBUs Supply of integrated Tele- ultrasound solutions with OPTIP products connected via Streambox to GE HealthCare ultrasound machines Digital After-sales assistance provided by the People Support SBU for Healthcare products offered by the Digital Healthcare SBU After-
Slide 8: Value Chain and Business Process
VALUE CHAIN AND BUSINESS PROCESS Predict sells its products both through direct orders from private customers and through bids open to public and private entities. ORDERS FROM Pre-sales/product Offering Sales Post-sales PRIVATE CUSTOMERS marketing Imaging EDUCATION LAUNCH People Support RESEARCH TAK
Slide 9: Suppliers and Clients
SUPPLIERS AND CLIENTS SUPPLIERS CLIENTS ✓ Manufacturers of Imaging Equipment PUBLIC: ✓ university clinics ✓ Companies providing in vivo diagnostic Imaging ✓ IRCCS ✓ Public Hospitals services ✓ Universities ✓ Primary and ✓ Manufacturers of systems for gas chromatography Secondary Schools and mass spe
Slide 10: Research and Development
RESEARCH AND DEVELOPMENT • 2016-21: completed breath sample collection system (Mistral Sampler) and CE mark • 4Q 2021 -1H22: The Mistral Lab breath analysis laboratory has been built and launched MISTRAL • 3Q 2022: Process automation of the Lab's examination procedures • 1Q 2023: AI algorithms have
Slide 11: Patents and CE Trademarks
PATENTS AND CE TRADEMARKS 08/2017 09/2021 Filing of European patent application 12/2019 Patent granted in the USA, Filing of CE trademark no. 11,122,164 B2 08/2018 02/2020 03/2023 Filing of international PCT patent Filing of CE trademark for the Utility model granted in Italy application new product
Slide 12: Reference Markets and Drivers
REFERENCE MARKETS AND DRIVERS Predict operates in 3 market niches in the Healthcare sector, growing globally: 1 Imaging 2 Breath analysis 3 Digital Health Tech A t I n t e r n a t i o n a l l e v e l $ bn +6% $ bn +16% $ bn +28% CAGR 2023-2028 CAGR 2022-2030 CAGR 2022-2030 57 4 1,532 43 45 48 50 53
Slide 13: Management Team & Key People
MANAGEMENT TEAM & KEY PEOPLE Isabella Cafagna Loredana Amoruso Angelo Gigante Vice President and CEO CEO Founder, President, CEO SBU Mistral Director Tender and Legal Affairs Manager 20+ years of experience 10+ years of experience 10+ years of experience 2008: founds Predict 2015-today: Sales Accoun
Slide 14: Shareholding and Governance
SHAREHOLDING AND GOVERNANCE SHAREHOLDING GOVERNANCE Board of Directors** Angelo Aurelio Gigante Angelo Aurelio Paola President and CEO Gigante Sciancalepore Isabella Cafagna Loredana Amoruso Vice President , Executive Director Executive Director 51% 49% Rocco Dichio Valeria Stucci Director Director
Slide 15: ESG
ESG Certifications E S G Scope 1 Emissions Production Bonuses Gender Equality Committee 6 tCO₂e total | 2.2 tCO₂e per FTE Implementation of a PRB linked 40% Male Employees to the achievemnt of EBITDA- 60% Female Employees Scope 2 Emissions related objectives ESG Committee 5.8 tCO₂e total | 0.75 tCO₂
Slide 16: Growth Strategies
GROWTH STRATEGIES Development of ▪ R&D and partnerships with clinical research centers ▪ Hiring of new professional roles, strengthening of commercial functions, innovative SBUs and product development with a focus on ▪ Implementation of a network of Mistral Labs in Italy Mistral ▪ Development of pa
Slide 17: Financial Highlights FY24 vs FY23 & FY22
FINANCIAL HIGHLIGHTS FY24 vs FY23 & FY22 Revenue / VoP (€mn) EBITDA (€mn) Net Result (€mn) EBITDA% FY24: 12% (vs.11% FY23) VoP VoP ReV ReV VoP ReV NFI / NFI Adj. (€mn) Equity (€mn) NFI Adj. NFI Adj. NFI Adj. 17
Slide 18: FY2024 vs FY2023 Income Statement
FY2024 vs FY2023 INCOME STATEMENT Riclassified Income Statement (Euro/000) 31.12.2024 %(*) 31.12.2023 %(*) Var. % Sales Revenues 6,626 100.0% 7,190 100.0% -7.8% Other revenues and income 712 10.7% 829 11.5% -14.1% Value of Production 7,337 110.7% 8,019 111.5% -8.5% Costs of raw materials, components
Slide 19: FY2024 vs FY2023 SBU Income Statement: Imaging
FY2024 vs FY2023 SBU INCOME STATEMENT Imaging (*) (*) SBU Imaging Income Statement 31.12.2024 % 31.12.2023 % Var. % (Data in Euro/000) 2024 - 2023 Sales Revenues 5,173 100.0% 5,192 100.0% -0.4% Other revenues and income 23 0.4% 33 0.6% -30.3% Value of Production 5,196 100.4% 5,224 100.6% -0.5% Costs
Slide 20: FY2024 vs FY2023 SBU Income Statement: People Support
FY2024 vs FY2023 SBU INCOME STATEMENT People Support (*) (*) SBU People Support Income Statement 31.12.2024 % 31.12.2023 % Var. % (Data in Euro/000) 2024 – 2023 Sales Revenues 905 100.0% 1.158 100.0% -21.8% Other revenues and income 5 0.5% 8 0.7% -37.5% Value of Production 910 100.5% 1.166 100.7% -2
Slide 21: FY2024 vs FY2023 SBU Income Statement: Mistral
FY2024 vs FY2023 SBU INCOME STATEMENT Mistral (*) (*) SBU Mistral Income Statement 31.12.2024 % 31.12.2023 % Var. % (Data in Euro/000) 2024 - 2023 Sales Revenues 258 100.0% 311 100.0% -17.0% Other revenues and income 421 163.5% 400 128.8% 5.3% Value of Production 679 263.5% 711 228.8% -4.5% Costs of
Slide 22: FY2024 vs FY2023 SBU Income Statement: Digital Healthcare
FY2024 vs FY2023 SBU INCOME STATEMENT Digital Healthcare (*) (*) SBU Digital Healthcare Income Statement 31.12.2024 % 31.12.2023 % Var. % (Data in Euro/000) 2024 - 2023 Sales Revenues 290 100.0% 529 100.0% -45.2% Other revenues and income 263 90.8% 388 73.3% -32.2% Value of Production 552 190.8% 917
Slide 23: FY2024 vs FY2023 Balance Sheet
FY2024 vs FY2023 BALANCE SHEET Riclassified Balance Sheet (Euro/000) 31.12.2024 %(*) 31.12.2023 %(*) Var. % Intangible fixed assets 790 39.4% 440 40.1% 79.5% Tangible fixed assets 563 28.1% 667 60.7% -15.6% Financial fixed assets 633 31.6% 650 59.2% -2.6% Net fixed assets ** 1,987 99.1% 1,758 159.9%
Slide 24: Investment Highlights
INVESTMENT HIGHLIGHTS High-growth markets in Healthcare Strong demand for diagnostic technologies, leading to efficient offerings at lower costs "Turnkey" solutions High level of know-how and track record for breath analysis laboratories at University acquired by top management, Hospitals, IRCCS, an
Slide 25: Key Takeaways
KEY TAKEAWAYS 1Q2025 2Q2025 3Q2025 4Q2025 In 2025 Predict will focus on: SBU Imaging: Achievements: • Acquisition of new clients • Agreement with Caresmed for distribution of • Diversification of product portfolio new technologies for the prevention of chronic • Planned expansion of the business in
Slide 26: Predict on EGM
PREDICT ON EGM Market data IDENTIFIERS & STOCK Stock code PRE ISIN Ordinary Shares IT0005611071 N. Ordinary Shares 5,419,500 N. Multiple voting shares1 1,800,000 N. PAS2 300,000 IPO DATA Start date of trading 30/09/2024 Capital raised in IPO (pre greenshoe) € 1,519,500 Admission price € 1.00 IPO cap
Slide 27: Annex
LIFE CARE ANNEX
Slide 28: Videos
VIDEOS SUPPLY OF TECHNOLOGIES FOR BREATH ANALYSIS CONSTRUCTION OF “TURNKEY” BREATH ANALYSIS LABORATORIES SUPPLY OF AR TECHNOLOGIES FOR TELE-ULTRASOUND SUPPLY OF AR TECHNOLOGIES FOR EDUCATION AND TRAINING SUPPLY OF HUMANOID ROBOTS FOR THE DEPARTMENT PREDICT SITE MISTRAL LAB 28
Slide 29: Marketing Mix
MARKETING MIX Imaging People Support Mistral Digital Healthcare - Personal selling Promotion - Industry trade fairs - Websites - Dissemination - Direct sale Placement - Public Tenders - Specialized sellers - Distribution policies|Price lists Pricing - Tailor made / Customed - Fixed+renewal / Value-b
Slide 30: Disclaimer
DISCLAIMER This document has been prepared by Predict S.p.A. (the "Company") for informational purposes only. It contains only summarized information and, therefore, is of a preliminary nature. Additionally, it has been prepared without claiming to be exhaustive. This presentation ("Presentation") a
Slide 31: Predict Investor Relations
PREDICT Viale Adriatico c/o Fiera del Levante Pad. 105 - 70132 Bari Tel. +39 080 893 3754 predictcare.it INVESTOR RELATIONS MANAGER INVESTOR RELATIONS ADVISOR Angelo Ceci, CFO - Predict Chiara Cardelli, Associate - KT&Partners E-mail: investor.relator@predictcare.it E-mail: ccardelli@ktepartners.com
Predict — KT&Partners Annual Investors Summit Day 2025 on 6ix